1
|
García-Lamas L, Lozano D, Jiménez-Díaz V, Bravo-Giménez B, Sánchez-Salcedo S, Jiménez-Holguín J, Abella M, Desco M, Vallet-Regi M, Cecilia-López D, Salinas AJ. Enriched mesoporous bioactive glass scaffolds as bone substitutes in critical diaphyseal bone defects in rabbits. Acta Biomater 2024; 180:104-114. [PMID: 38583750 DOI: 10.1016/j.actbio.2024.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 03/23/2024] [Accepted: 04/02/2024] [Indexed: 04/09/2024]
Abstract
In the field of orthopedic surgery, there is an increasing need for the development of bone replacement materials for the treatment of bone defects. One of the main focuses of biomaterials engineering are advanced bioceramics like mesoporous bioactive glasses (MBG´s). The present study compared the new bone formation after 12 weeks of implantation of MBG scaffolds with composition 82,5SiO2-10CaO-5P2O5-x 2.5SrO alone (MBGA), enriched with osteostatin, an osteoinductive peptide, (MBGO) or enriched with bone marrow aspirate (MBGB) in a long bone critical defect in radius bone of adult New Zealand rabbits. New bone formation from the MBG scaffold groups was compared to the gold standard defect filled with iliac crest autograft and to the unfilled defect. Radiographic follow-up was performed at 2, 6, and 12 weeks, and microCT and histologic examination were performed at 12 weeks. X-Ray study showed the highest bone formation scores in the group with the defect filled with autograft, followed by the MBGB group, in addition, the microCT study showed that bone within defect scores (BV/TV) were higher in the MBGO group. This difference could be explained by the higher density of newly formed bone in the osteostatin enriched MBG scaffold group. Therefore, MBG scaffold alone and enriched with osteostatin or bone marrow aspirate increase bone formation compared to defect unfilled, being higher in the osteostatin group. The present results showed the potential to treat critical bone defects by combining MBGs with osteogenic peptides such as osteostatin, with good prospects for translation into clinical practice. STATEMENT OF SIGNIFICANCE: Treatment of bone defects without the capacity for self-repair is a global problem in the field of Orthopedic Surgery, as evidenced by the fact that in the U.S alone it affects approximately 100,000 patients per year. The gold standard of treatment in these cases is the autograft, but its use has limitations both in the amount of graft to be obtained and in the morbidity produced in the donor site. In the field of materials engineering, there is a growing interest in the development of a bone substitute equivalent. Mesoporous bioactive glass (MBG´s) scaffolds with three-dimensional architecture have shown great potential for use as a bone substitutes. The osteostatin-enriched Sr-MBG used in this long bone defect in rabbit radius bone in vivo study showed an increase in bone formation close to autograft, which makes us think that it may be an option to consider as bone substitute.
Collapse
Affiliation(s)
- Lorena García-Lamas
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación I+12, Madrid, España.
| | - Daniel Lozano
- Instituto de Investigación I+12, Madrid, España; Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, España
| | - Verónica Jiménez-Díaz
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación I+12, Madrid, España
| | - Beatriz Bravo-Giménez
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación I+12, Madrid, España
| | - Sandra Sánchez-Salcedo
- Instituto de Investigación I+12, Madrid, España; Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, España
| | - Javier Jiménez-Holguín
- Instituto de Investigación I+12, Madrid, España; Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, España
| | - Mónica Abella
- Departamento de Bioingeniería, Universidad Carlos III de Madrid, España; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, España
| | - Manuel Desco
- Departamento de Bioingeniería, Universidad Carlos III de Madrid, España; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, España
| | - María Vallet-Regi
- Instituto de Investigación I+12, Madrid, España; Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, España
| | - David Cecilia-López
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación I+12, Madrid, España
| | - Antonio Jesús Salinas
- Instituto de Investigación I+12, Madrid, España; Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, España.
| |
Collapse
|
2
|
Wang J, Liu M, Yang C, Pan Y, Ji S, Han N, Sun G. Biomaterials for bone defect repair: Types, mechanisms and effects. Int J Artif Organs 2024; 47:75-84. [PMID: 38166512 DOI: 10.1177/03913988231218884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2024]
Abstract
Bone defects or bone discontinuities caused by trauma, infection, tumours and other diseases have led to an increasing demand for bone grafts and biomaterials. Autologous bone grafts, bone grafts with vascular tips, anastomosed vascular bone grafts and autologous bone marrow components are all commonly used in clinical practice, while oversized bone defects require the use of bone tissue engineering-related biomaterials to repair bone defects and promote bone regeneration. Currently, inorganic components such as polysaccharides and bioceramics, as well as a variety of bioactive proteins, metal ions and stem cells can be loaded into hydrogels or 3D printed scaffold materials to achieve better therapeutic results. In this review, we provide an overview of the types of materials, applications, potential mechanisms and current developments in the repair of bone defects.
Collapse
Affiliation(s)
- Jiaming Wang
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Mingchong Liu
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Chensong Yang
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Yutao Pan
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Shengchao Ji
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Ning Han
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Guixin Sun
- Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| |
Collapse
|
3
|
García-Lamas L, Sánchez-Salcedo S, Jiménez-Díaz V, Bravo-Giménez B, Cabañas MV, Peña J, Román J, Jiménez-Holguín J, Abella M, Desco M, Lozano D, Cecilia-López D, Salinas AJ. Desing and comparison of bone substitutes. Study of in vivo behavior in a rabbit model. Rev Esp Cir Ortop Traumatol (Engl Ed) 2023; 67:324-333. [PMID: 36646252 DOI: 10.1016/j.recot.2022.12.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 12/01/2022] [Accepted: 12/03/2022] [Indexed: 01/15/2023] Open
Abstract
AIM Compare bone formation capacity in vivo of two types of biomaterials designed as bone substitutes with respect to iliac crest autograft, one based on carbonate hydroxyapatites and the other one on bioactive mesoporous glass. MATERIALS AND METHODS Experimental study consisting on 14 adult female New Zeland rabbits where a critical defect was made in the rabbit radius bone. The sample was divided into four groups: defect without material, with iliac crest autograft, with carbonatehydroxyapatite support, and with bioactive mesoporous glass support. Serial X-ray studies were carried out at 2, 4, 6 and 12 weeks and a microCT study at euthanasia at 6 and 12 weeks. RESULTS In the X-ray study, autograft group showed the highest bone formation scores. Both groups of biomaterials presented bone formation similar and greater than the defect without material, but always less than in the autograft group. The results of the microCT study showed the largest bone volume in the study area in the autograft group. The groups with bone substitutes presented greater bone volume than the group without material but always less than in the autograft group. CONCLUSION Both supports seem to promote bone formation but are not capable of reproducing the characteristics of autograft. Due to their different macroscopic characteristics, each one could be suitable for a different type of defect.
Collapse
Affiliation(s)
- L García-Lamas
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre; Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España.
| | - S Sánchez-Salcedo
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España; CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, España
| | - V Jiménez-Díaz
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre; Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - B Bravo-Giménez
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre; Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - M V Cabañas
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - J Peña
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - J Román
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - J Jiménez-Holguín
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - M Abella
- Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, España
| | - M Desco
- Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, España
| | - D Lozano
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España; CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, España
| | - D Cecilia-López
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre; Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España
| | - A J Salinas
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, España; CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, España
| |
Collapse
|
4
|
García-Lamas L, Sánchez-Salcedo S, Jiménez-Díaz V, Bravo-Giménez B, Cabañas MV, Peña J, Román J, Jiménez-Holguín J, Abella M, Desco M, Lozano D, Cecilia-López D, Salinas AJ. [Translated article] Design and comparison of bone substitutes. Study of in vivo behaviour in a rabbit model. Rev Esp Cir Ortop Traumatol (Engl Ed) 2023; 67:T324-T333. [PMID: 36940846 DOI: 10.1016/j.recot.2023.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 12/03/2022] [Indexed: 03/23/2023] Open
Abstract
AIM To compare the in vivo bone formation capacity of of biomaterials designed as bone substitutes with respect to iliac crest autograft, one based on carbonate hydroxiapatite and the other one on bioactive mesoporous glass. MATERIALS AND METHODS Experimental study consisting on 14 adult female New Zeland rabbits where a critical defect was made in the rabbit radius bone. The sample was divided into four groups: defect without material, with iliac crest autograft, with carbonatehydroxyapatite scaffold, and with bioactive mesoporous glass scaffold. Serial X-ray studies were carried out at 2, 4, 6 and 12 weeks and a microCT study at euthanasia at 6 and 12 weeks. RESULTS In the X-ray study, autograft group showed the highest bone formation scores. Both groups of biomaterials presented bone formation similar and greater than the defect without material, but always less than in the autograft group. The results of the microCT study showed the largest bone volume in the study area in the autograft group. The groups with bone substitutes presented greater bone volume than the group without material but always less than the autograft group. CONCLUSION Both scaffolds seem to promote bone formation but are not capable of reproducing the characteristics of autograft. Due to their different macroscopic characteristics, each one could be suitable for a different type of defect.
Collapse
Affiliation(s)
- L García-Lamas
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain.
| | - S Sánchez-Salcedo
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain
| | - V Jiménez-Díaz
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - B Bravo-Giménez
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - M V Cabañas
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - J Peña
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - J Román
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - J Jiménez-Holguín
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - M Abella
- Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, Spain
| | - M Desco
- Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, Spain
| | - D Lozano
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain
| | - D Cecilia-López
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain
| | - A J Salinas
- Departamento de Química en Ciencias Farmaceúticas, Universidad Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
5
|
Zalama E, Karrouf G, Rizk A, Salama B, Samy A. Does zinc oxide nanoparticles potentiate the regenerative effect of platelet-rich fibrin in healing of critical bone defect in rabbits? BMC Vet Res 2022; 18:130. [PMID: 35366880 PMCID: PMC8976312 DOI: 10.1186/s12917-022-03231-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Accepted: 03/15/2022] [Indexed: 11/20/2022] Open
Abstract
Background Many encouraging studies confirmed the ability of Zinc Oxide Nanoparticles (ZnONPs) in accelerating bone growth and mineralization. The use of Platelet Rich-Fibrin (PRF) as a sole filling material for large segmental bone defects remains questionable. The objectives are to investigate the regenerative efficacy of autologous Platelet Rich-Fibrin (PRF) and Zinc Oxide Nanoparticles (ZnONPs) in repairing large segmental bone ulnar defects in a randomized controlled study in rabbits using computed tomographic interpretations. A 12 mm critical size defect was surgically induced in the ulna of 30 rabbits (n = 10/ group). In the control group, the defect was left empty. In the PRF group, the defect is filled with PRF. In the PRF/ZnONPs group, the defect is filled with PRF that was inoculated with 0.1 ml of 0.2% ZnONPs. Radiologic healing capacity was evaluated at the first, second, and third postoperative months. Results Statistical analysis showed significant differences in the radiologic healing scores between the groups (P = 0.000–0.0001) at all-time points (P = 0.000–0.047) during the study. Conclusion Rabbits in the PRF/ZnONPs group showed the highest appreciable bone quality and quantity followed by the PRF group with high quantity but low bone quality meanwhile, rabbits in the control group showed minimal quantity but medium bone quality. Interestingly, the addition of ZnONPs to PRF can accelerate the healing of ulnar critical-size defects in rabbits.
Collapse
|
6
|
Wickramasinghe ML, Dias GJ, Premadasa KMGP. A novel classification of bone graft materials. J Biomed Mater Res B Appl Biomater 2022; 110:1724-1749. [DOI: 10.1002/jbm.b.35029] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2021] [Revised: 01/20/2022] [Accepted: 01/21/2022] [Indexed: 12/19/2022]
Affiliation(s)
- Maduni L. Wickramasinghe
- Department of Biomedical Engineering General Sir John Kotelawala Defense University Ratmalana Sri Lanka
| | - George J. Dias
- Department of Anatomy, School of Medical Sciences University of Otago Dunedin New Zealand
| | | |
Collapse
|
7
|
Kanjilal D, Grieg C, Culbertson MD, Lin SS, Vives M, Benevenia J, O'Connor JP. Improved osteogenesis in rat femur segmental defects treated with human allograft and zinc adjuvants. Exp Biol Med (Maywood) 2021; 246:1857-1868. [PMID: 34038225 DOI: 10.1177/15353702211019008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Bone allograft is widely used to treat large bone defects or complex fractures. However, processing methods can significantly compromise allograft osteogenic activity. Adjuvants that can restore the osteogenic activity of processed allograft should improve clinical outcomes. In this study, zinc was tested as an adjuvant to increase the osteogenic activity of human allograft in a Rag2 null rat femoral defect model. Femoral defects were treated with human demineralized bone matrix (DBM) mixed with carboxy methyl cellulose containing ZnCl2 (0, 75, 150, 300 µg) or Zn stearate (347 µg). Rat femur defects treated with DBM-ZnCl2 (75 µg) and DBM-Zn stearate (347 µg) showed increased calcified tissue in the defect site compared to DBM alone. Radiograph scoring and µCT (microcomputed tomography) analysis showed an increased amount of bone formation at the defects treated with DBM-Zn stearate. Use of zinc as an adjuvant was also tested using human cancellous bone chips. The bone chips were soaked in ZnCl2 solutions before being added to defect sites. Zn adsorbed onto the chips in a time- and concentration-dependent manner. Rat femur defects treated with Zn-bound bone chips had more new bone in the defects based on µCT and histomorphometric analyses. The results indicate that zinc supplementation of human bone allograft improves allograft osteogenic activity in the rat femur defect model.
Collapse
Affiliation(s)
- Deboleena Kanjilal
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA.,School of Graduate Studies, Rutgers-Newark Health Science Campus, Newark, NJ 07103, USA
| | - Christopher Grieg
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA.,School of Graduate Studies, Rutgers-Newark Health Science Campus, Newark, NJ 07103, USA
| | - Maya Deza Culbertson
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| | - Sheldon S Lin
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| | - Michael Vives
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| | - Joseph Benevenia
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| | - J Patrick O'Connor
- Department of Orthopaedics, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| |
Collapse
|
8
|
Amelia F, Abbas B, Darwis D, Estuningsih S, Noviana D. Effects of bone types, particle sizes, and gamma irradiation doses in feline demineralized freeze-dried bone allograft. Vet World 2020; 13:1536-1543. [PMID: 33061224 PMCID: PMC7522947 DOI: 10.14202/vetworld.2020.1536-1543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Accepted: 06/09/2020] [Indexed: 11/16/2022] Open
Abstract
Background and Aim: Fracture cases significantly increase recently, demanding high quality of bone graft materials. This research aimed to evaluate the effects of bone types, particle sizes, and gamma irradiation doses on morphological performance and cell viability of feline demineralized freeze-dried bone allograft (DFDBA) through an in vitro study. Materials and Methods: Feline DFDBA derived from feline cortical and cancellous long bones was processed into four different sizes: Group A (larger than 1000 µm), B (841-1000 µm), C (420-840 µm), and D (250-419 µm) for each type of bones. The materials were then irradiated with two doses of gamma rays, 15 and 25 kGy, resulting in 16 variants of feline DFDBA. The surfaces of each material were then observed with the scanning electron microscope (SEM). The in vitro evaluation of feline DFDBA was then performed using 3-(4,5-dimethythiazol-2)-2,5-diphenyltetrazolium bromide (MTT) assay with calf pulmonary artery endothelial cells. Results: The MTT assay results showed that the lowest inhibition rate (14.67±9.17 %) achieved by feline DFDBA in Group A derived from cortical bones irradiated with 15 kGy. Group D generally showed high inhibition rate in both cancellous and cortical bones, irradiated with either 15 or 25 kGy. The SEM results showed that cancellous and cortical bones have numerous macropores and micropores structure in 170× and 3000×, respectively. Conclusion: The material derived from cortical bones in Group A (larger than 1000 µm in particle size) irradiated with 15 kGy is the best candidate for further development due to its abundance of micropores structure and ability in preserving the living cells.
Collapse
Affiliation(s)
- Frizky Amelia
- Program Study of Animal Biomedical Science, Graduate School of IPB University, Bogor, Jawa Barat 16680, Indonesia.,Diagnostic Imaging Center, Veterinary Teaching Hospital, Faculty of Veterinary Medicine IPB University, Bogor, Jawa Barat 16680, Indonesia
| | - Basril Abbas
- Centre for Isotopes and Radiation Application, National Nuclear Energy Agency (BATAN), Jakarta Selatan, DKI Jakarta 12440, Indonesia
| | - Darmawan Darwis
- Centre for Isotopes and Radiation Application, National Nuclear Energy Agency (BATAN), Jakarta Selatan, DKI Jakarta 12440, Indonesia
| | - Sri Estuningsih
- Department of Clinic Reproduction and Pathology, Faculty of Veterinary Medicine IPB University, Bogor, Jawa Barat 16680, Indonesia
| | - Deni Noviana
- Diagnostic Imaging Center, Veterinary Teaching Hospital, Faculty of Veterinary Medicine IPB University, Bogor, Jawa Barat 16680, Indonesia.,Department of Clinic Reproduction and Pathology, Faculty of Veterinary Medicine IPB University, Bogor, Jawa Barat 16680, Indonesia
| |
Collapse
|
9
|
Albulescu R, Popa AC, Enciu AM, Albulescu L, Dudau M, Popescu ID, Mihai S, Codrici E, Pop S, Lupu AR, Stan GE, Manda G, Tanase C. Comprehensive In Vitro Testing of Calcium Phosphate-Based Bioceramics with Orthopedic and Dentistry Applications. MATERIALS 2019; 12:ma12223704. [PMID: 31717621 PMCID: PMC6888321 DOI: 10.3390/ma12223704] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Revised: 10/29/2019] [Accepted: 11/05/2019] [Indexed: 02/07/2023]
Abstract
Recently, a large spectrum of biomaterials emerged, with emphasis on various pure, blended, or doped calcium phosphates (CaPs). Although basic cytocompatibility testing protocols are referred by International Organization for Standardization (ISO) 10993 (parts 1-22), rigorous in vitro testing using cutting-edge technologies should be carried out in order to fully understand the behavior of various biomaterials (whether in bulk or low-dimensional object form) and to better gauge their outcome when implanted. In this review, current molecular techniques are assessed for the in-depth characterization of angiogenic potential, osteogenic capability, and the modulation of oxidative stress and inflammation properties of CaPs and their cation- and/or anion-substituted derivatives. Using such techniques, mechanisms of action of these compounds can be deciphered, highlighting the signaling pathway activation, cross-talk, and modulation by microRNA expression, which in turn can safely pave the road toward a better filtering of the truly functional, application-ready innovative therapeutic bioceramic-based solutions.
Collapse
Affiliation(s)
- Radu Albulescu
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
- Department Pharmaceutical Biotechnology, National Institute for Chemical-Pharmaceutical R&D, 031299, Bucharest, Romania
| | - Adrian-Claudiu Popa
- National Institute of Materials Physics, 077125 Magurele, Romania (G.E.S.)
- Army Centre for Medical Research, 010195 Bucharest, Romania
| | - Ana-Maria Enciu
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
- Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050047 Bucharest, Romania
| | - Lucian Albulescu
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
| | - Maria Dudau
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
- Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050047 Bucharest, Romania
| | - Ionela Daniela Popescu
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
| | - Simona Mihai
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
| | - Elena Codrici
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
| | - Sevinci Pop
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
| | - Andreea-Roxana Lupu
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
- Cantacuzino National Medico-Military Institute for Research and Development, 050096 Bucharest, Romania
| | - George E. Stan
- National Institute of Materials Physics, 077125 Magurele, Romania (G.E.S.)
| | - Gina Manda
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
| | - Cristiana Tanase
- Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, 050096 Bucharest, Romania; (R.A.); (L.A.); (M.D.); (I.D.P.); (S.M.); (E.C.); (S.P.); (A.-R.L.); (G.M.)
- Cajal Institute, Titu Maiorescu University, 004051 Bucharest, Romania
- Correspondence:
| |
Collapse
|
10
|
Tao C, Lina X, Changxuan W, Cong L, Xiaolan Y, Tao H, Hong A. Orthogonal test design for the optimization of superparamagnetic chitosan plasmid gelatin microspheres that promote vascularization of artificial bone. J Biomed Mater Res B Appl Biomater 2019; 108:1439-1449. [PMID: 31605570 PMCID: PMC7187448 DOI: 10.1002/jbm.b.34491] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Revised: 08/06/2019] [Accepted: 09/02/2019] [Indexed: 12/20/2022]
Abstract
The optimal conditions for the preparation of superparamagnetic chitosan plasmid (pReceiver‐M29‐VEGF165/DH5a) gelatin microspheres (SPCPGMs) were determined. Then, the performance of the SPCPGMs during neovascularization was evaluated in vivo. The SPCPGMs were prepared through a cross‐linking curing method and then filled into the hollow scaffold of an artificial bone. Neovascularization at the bone defect position was histologically examined in samples collected 2, 4, 6, and 8 weeks after the operation. The cellular magnetofection rate of superparamagnetic chitosan nanoparticles/plasmid (pReceiver‐M29‐VEGF165/DH5a) complexes reached 1–3% under static magnetic field (SMF). Meanwhile, the optimal conditions for SPCPGM fabrication were 20% Fe3O4 (w/v), 4 mg of plasmid, 5.3 mg of glutaraldehyde, and 500 rpm of emulsification rotate speed. Under oscillating magnetic fields (OMFs), 4–6 μg of plasmids was released daily for 21 days. Under the combined application of SMF and OMF, evident neovascularization occurred at the bone defect position 6 weeks after the operation. This result is expected to provide a new type of angiogenesis strategy for the research of bone tissue engineering.
Collapse
Affiliation(s)
- Chen Tao
- Department of Orthopaedics, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, P.R China, Chongqing Key Laboratory of Pediatrics, Chongqing Engineering Research Center of Stem Cell Therapy
| | - Xie Lina
- Department of Orthopaedics, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, P.R China, Chongqing Key Laboratory of Pediatrics, Chongqing Engineering Research Center of Stem Cell Therapy
| | - Wang Changxuan
- Department of Orthopaedics, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, P.R China, Chongqing Key Laboratory of Pediatrics, Chongqing Engineering Research Center of Stem Cell Therapy
| | - Luo Cong
- Department of Orthopaedics, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, P.R China, Chongqing Key Laboratory of Pediatrics, Chongqing Engineering Research Center of Stem Cell Therapy
| | - Yang Xiaolan
- Department of Pharmacology, Chongqing Medical University, Yuzhong District, Yixueyuan Road1#, Chongqing, 400016, China
| | - Huang Tao
- Department of Orthopaedics, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, P.R China, Chongqing Key Laboratory of Pediatrics, Chongqing Engineering Research Center of Stem Cell Therapy
| | - An Hong
- Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Youyi Road 1#, Chongqing, 400016, China
| |
Collapse
|